1. Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective.
- Author
-
Abraham E, Ahmadian BB, Holderness K, Levinson Y, and McAfee E
- Subjects
- Bioreactors, Cell- and Tissue-Based Therapy, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Biotechnology instrumentation, Biotechnology methods, Biotechnology trends, Cell Culture Techniques instrumentation, Cell Culture Techniques methods, Cell Culture Techniques trends
- Abstract
As cell therapy processes mature from benchtop research protocols to industrial processes capable of manufacturing market-relevant numbers of doses, new cell manufacturing platforms are required. Here we give an overview of the platforms and technologies currently available to manufacture allogeneic cell products, such as mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), and technologies for mass production of autologous cell therapies via scale-out. These technologies include bioreactors, microcarriers, cell separation and cryopreservation equipment, molecular biology tools for iPSC generation, and single-use controlled-environment systems for autologous cell production. These platforms address the challenges of manufacturing cell products in greater numbers while maintaining process robustness and product quality.
- Published
- 2018
- Full Text
- View/download PDF